Stereotactic body radiation therapy combined with Nexavar showed a clinically important improvement in overall survival in ...

A 69-year-old man from Arizona tragically died after developing an aggressive form of cancer from a liver transplant, a rare ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

The US Food and Drug Administration has granted orphan drug designation (ODD) to Tempest Therapeutics' oral, selective ...

Patients with indeterminate chronic hepatitis B (CHB) phase are at risk of progressing to advanced liver disease and hepatocellular carcinoma (HCC), according to study results published in the Journal ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

The following is a summary of “Development models to predict complication and prognosis following liver resection for ...

Naya Biosciences Inc. has expanded its bifunctional antibody pipeline to include NY-500, a novel PD-1 x VEGF tetravalent bifunctional antibody for the treatment of hepatocellular carcinoma (HCC) and ...

Liver cells attempt to shut down as a defense mechanism against cancer, but this strategy is not particularly effective.

Alcohol-associated hepatitis (AH) is a critical global health issue characterized by acute liver inflammation and an elevated ...

PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications• NAYA aiming to ...

But the man’s condition worsened, progressing into cirrhosis and eventually hepatocellular carcinoma, also known as liver ...